「pr」の検索結果
234件：161～165件目を表示
-
ical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (He...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
vel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
忌です。 ■参考 米国FDAの亜硫酸塩を含有する医療用医薬品による過敏症に関する医療関係者向けの注意喚起の内容 を、以下のサイトよりご確認いただけます。 FDA alerts health care professionals, compounders and patients of potential safety risks associated with sulfite- containin...
https://www.senju.co.jp/system/files/revision_news/2026-03/BRN_202603_Revised Info.pdf -
Sales Trends and Breakdown | About Senju | SENJU Pharmaceutical
Company Profile Milestones in Our History
https://www.senju.co.jp/english/about/sales.html -
Publications | Research & Development | SENJU Pharmaceutica
cine, Houston, Texas, USA American Journal of Ophthalmology. 2026:284:216-225. VIEW PUBLICATION Comprehensive genotoxicity and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient rec...
http://www.senju.co.jp/english/rd/thesis/